secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hemab Therapeutics Holdings, Inc. (COAG)
CIK:        0002114044
Form:       8-K
Filed at:   2026-05-11T20:01:15+00:00
Accession:  0001193125-26-216699
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Laura Tadvalkar resigns from Hemab Therapeutics board effective May 8, 2026
--------------------------------------------------------------------------------

- Laura Tadvalkar, Ph.D., resigned as a member of the Board, effective May 8, 2026.
- Resignation not related to any disagreement with the Company on operations, policies or practices.
- No replacement director announced; Board size reduced by one.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2114044/000119312526216699/0001193125-26-216699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2114044/000119312526216699/d141757d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer